PIOL suitable for myopic eyes

Article

The acrylic angle-supported phakic IOL (PIOL) provides moderate one-year rotational stability, making it a successful treatment option for myopic eyes, claims a new paper.

The acrylic angle-supported phakic IOL (PIOL) provides moderate one-year rotational stability, making it a successful treatment option for myopic eyes, claims a new paper.

Dr Omid Kermani et al., Augenklinik am Neumarkt, Cologne, Germany, evaluated the rotational stability of the PIOL 12 months after implantation in fifty eyes of 28 patients with myopia. Digital overlay of the ocular photographs, taken within two weeks of implantation, were used to assess IOL rotation.

The secondary outcomes included spherical equivalent, refractive sphere and cylinder, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). All measurements were analysed preoperatively and three months after implantation.

All patients underwent successful IOL implantation and follow-up. The outcomes presented a mean 12-month rotation of 11º and only 2% of eyes required additional laser adjustment by month 12, due to corneal astigmatism.

Outcomes improved at the three-month follow-up, with spherical equivalent at 0.35 ± 0.79 D, spherical refraction at 0.04 ± 0.82 D and cylindrical refraction at −0.77 ± 0.91 D.

Overall, the lens effectively corrects myopia but the rotation means it is unsuitable for cylinder correction.

The abstract can be viewed in the latest issue of the Journal of Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.